...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Targeting tropomyosin-receptor kinase fused gene in cancer.
【24h】

Targeting tropomyosin-receptor kinase fused gene in cancer.

机译:在癌症中靶向原肌球蛋白受体激酶融合基因。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Tropomyosin-receptor kinase fused gene (TRK-fused gene, TFG) encodes a protein which is a conserved regulator of protein secretion that localizes in the endoplasmic reticulum exit sites and controls the export of materials from the endoplasmic reticulum. It is important for intracellular trafficking of protein secretion. TFG belongs to the systems which control cell size, and is involved in regulatory mechanisms of apoptosis and cell proliferation. The TFG fusion proteins have been found to play a role in oncogenesis, with the activity of TFG fusion proteins promoting tumor development. In addition, TFG alone has been demonstrated to function like an oncoprotein; however, there are contradictory data suggesting TFG might act as a tumor suppressor. In this article, we will review the functions and regulation of TFG, the TFG fusion proteins, and the role of TFG in tumorigenesis. Finally, the potential of targeting TFG in cancer treatment is discussed.
机译:肌红蛋白受体激酶融合基因(TRK融合基因,TFG)编码一种蛋白质,是一种保守的蛋白质分泌调节剂,位于内质网出口位点并控制内质网的物质输出。这对于细胞内蛋白质分泌的运输很重要。 TFG属于控制细胞大小的系统,并参与凋亡和细胞增殖的调节机制。已经发现TFG融合蛋白在肿瘤发生中起作用,其中TFG融合蛋白的活性促进肿瘤的发展。此外,已证明单独的TFG可以像癌蛋白一样发挥作用。然而,有矛盾的数据表明TFG可能起抑癌作用。在本文中,我们将回顾TFG的功能和调节,TFG融合蛋白以及TFG在肿瘤发生中的作用。最后,讨论了靶向TFG在癌症治疗中的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号